Rockstar Breakfast - SOLD OUT

About the Rockstars

Hui Gao joined Agios in January 2020 as the head of Pharmacology, and then became the head of Translational Research in January 2023 and support drug discovery programs as well as translational research activities for the programs that are currently in clinical development. Prior to joining Agios, I worked at AstraZeneca and served as in vivo team lead of Hematologic disease cluster and PTL for drug discovery programs in hematology/oncology therapeutic area. Before Joining AstraZeneca, I worked at Novartis Institutes for Biomedical Research (NIBR) and served as the lead pharmacologist and PTL for a number of oncology discovery and translational programs. I received my PhD degree from China Pharmaceutic University and completed postdoctoral training at National Cancer Center of Singapore and Rutgers University.

Dr. Sarah Gheuens joined Agios in December 2019, became chief medical officer in September 2021 and took on the additional role of head of R&D in August 2022. She previously served as Agios’ head of clinical development for the genetically defined disease programs, as well as the interim head of regulatory affairs. She has been instrumental in completing the pivotal Phase 3 program for pyruvate kinase deficiency and leading simultaneous regulatory submissions to the FDA and EMA in this indication, as well as designing the pivotal programs for thalassemia, sickle cell disease and the pediatric indications. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA®. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. She serves on the Board of Directors for Viridian Therapeutics, Inc. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC, Boston, Mass., USA. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

Megan Wind-Rotolo is a Senior Director, Translational Medicine at Agios where she leads a team of scientists working to integrate scientific data across pre-clinical and clinical studies to better understand how our drugs work and how they can help patients.  Prior to joining Agios, Megan worked at Bristol-Myers Squibb, first as a Biomarker Lead in immunology, virology and oncology, before moving to a role as a Translational Medicine Team Lead.  She earned her PhD at Emory University in Atlanta and has completed two postdocs, one at University of Alabama at Birmingham and another at Johns Hopkins University. She has been a contributing author on over 60 scientific publications.